Sudhaker Rao is an Endocrinology/Metabolic physician affiliated with Henry Ford Health System. OpenAlex indexes 136 publications with 3,371 citations (h-index 26); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Sponsor: Henry Ford Health System
- A Randomized Study of Surgery vs No Surgery in Patients With Mild Asymptomatic Primary Hyperparathyroidism
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
28.5%l-Thyroxine11.5%Levothyroxine Sodium100%Part D<11 patientsParathyroid Hormone-Related Peptide Analog7.6%Tymlos100%Part D<11 patients+ 2 more classes in this area
Genitourinary & hormones
22.2%Estrogen Agonist/Antagonist16%Raloxifene Hcl100%Part D≥14 patientsAndrogens and estrogens6.2%Premarin100%Part D<11 patientsMetabolism & gastrointestinal
20.5%Vitamin D3 Analog8.3%Calcitriol100%Part D<11 patientsProvitamin D2 Compound6.6%Vitamin D2100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1994–2016 per NIH RePORTER. The latest:
- Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Henry Ford Health System
FY2016$315,525R01AR062103 - Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Henry Ford Health System
FY2015$315,563R01AR062103 - Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Henry Ford Health System
FY2014$315,563R01AR062103
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Shirish Gadgeel, MD
Henry Ford Health System
Marcus Zervos, MD
Henry Ford Health System
Adnan Munkarah, MD
Henry Ford Health System
George Alangaden, MD
Henry Ford Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”